IN2012DN01641A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01641A
IN2012DN01641A IN1641DEN2012A IN2012DN01641A IN 2012DN01641 A IN2012DN01641 A IN 2012DN01641A IN 1641DEN2012 A IN1641DEN2012 A IN 1641DEN2012A IN 2012DN01641 A IN2012DN01641 A IN 2012DN01641A
Authority
IN
India
Prior art keywords
compounds
pentoxifylline
derivatives
relates
novel
Prior art date
Application number
Inventor
Roger D Tung
Julie F Liu
Scott L Harbeson
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of IN2012DN01641A publication Critical patent/IN2012DN01641A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/10—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)

Abstract

This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.
IN1641DEN2012 2009-09-02 2010-09-02 IN2012DN01641A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23934209P 2009-09-02 2009-09-02
US12/873,991 US20110053961A1 (en) 2009-02-27 2010-09-01 Substituted xanthine derivatives
PCT/US2010/047708 WO2011028922A1 (en) 2009-09-02 2010-09-02 Substituted xanthine derivatives

Publications (1)

Publication Number Publication Date
IN2012DN01641A true IN2012DN01641A (en) 2015-06-05

Family

ID=43625765

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1641DEN2012 IN2012DN01641A (en) 2009-09-02 2010-09-02

Country Status (22)

Country Link
US (1) US20110053961A1 (en)
EP (2) EP2963040A1 (en)
JP (1) JP5292516B2 (en)
KR (1) KR101591137B1 (en)
CN (2) CN104478881A (en)
AU (1) AU2010289465B2 (en)
BR (1) BR112012008108B1 (en)
CA (1) CA2771123C (en)
DK (1) DK2473053T3 (en)
EA (1) EA023809B1 (en)
ES (1) ES2542401T3 (en)
HR (1) HRP20150797T1 (en)
HU (1) HUE026800T2 (en)
IN (1) IN2012DN01641A (en)
ME (1) ME02177B (en)
MX (1) MX2012002705A (en)
PH (1) PH12012500278A1 (en)
PL (1) PL2473053T3 (en)
PT (1) PT2473053E (en)
SI (1) SI2473053T1 (en)
WO (1) WO2011028922A1 (en)
ZA (1) ZA201201295B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090239886A1 (en) * 2008-02-29 2009-09-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US20100159034A1 (en) * 2008-12-15 2010-06-24 Auspex Pharmaceuticals, Inc. Pyrrolidinone inhibitors of pde-4
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
US9260432B2 (en) 2009-09-02 2016-02-16 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
JP2013503883A (en) * 2009-09-02 2013-02-04 コンサート ファーマシューティカルズ インコーポレイテッド Substituted xanthine derivatives
US9085788B2 (en) 2010-09-01 2015-07-21 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
WO2012031138A2 (en) * 2010-09-01 2012-03-08 Concert Pharmaceuticals, Inc. Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3-7-dimethyl-1h-purine-2,6(3h,7h)dione
US9074233B2 (en) 2010-09-01 2015-07-07 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
IN2014DN08443A (en) 2012-04-13 2015-05-08 Concert Pharmaceuticals Inc
WO2013159006A1 (en) * 2012-04-20 2013-10-24 Concert Pharmaceuticals, Inc. Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3,7-dimethyl-1h-purine-2,6(3h,7h)-dione
CN106456647A (en) * 2014-04-18 2017-02-22 康塞特医药品有限公司 Methods of treating hyperglycemia
WO2015175008A1 (en) * 2014-05-14 2015-11-19 Concert Pharmaceuticals, Inc. Methods of treating chronic kidney disease characterized by macroalbuminuria
WO2015184248A1 (en) * 2014-05-30 2015-12-03 Concert Pharmaceuticals, Inc. Methods of treating fibrotic diseases
CN111233863B (en) * 2014-10-09 2022-10-25 广东众生睿创生物科技有限公司 Hydroxypurine compounds and their applications
USRE49128E1 (en) 2014-10-09 2022-07-12 Guangdong Raynovent Biotech Co., Ltd. Hydroxyl purine compounds and applications thereof
CN107709323B (en) * 2015-05-20 2020-11-20 广东众生睿创生物科技有限公司 Hydroxypurine compounds and their applications
CN108137592B (en) * 2015-11-03 2021-03-05 纽弗姆制药有限公司 Deuterated compounds and compositions and methods thereof for treating leukemia
WO2017087207A1 (en) * 2015-11-16 2017-05-26 NeuForm Pharmaceuticals, Inc. Deuterated compounds for treating hematologic malignant, inflammatory and autoimmune diseases
EP4034101A1 (en) * 2019-09-25 2022-08-03 Goldfinch Bio, Inc. Xanthine cb1 inhibitors
CN111440041B (en) * 2020-05-19 2021-03-05 北京理工大学 A kind of synthetic method of toluene-d8
CN114380829A (en) * 2021-12-28 2022-04-22 赤峰万泽药业股份有限公司 A kind of pentoxifylline and its synthetic method and application
CN118684672A (en) * 2023-03-24 2024-09-24 陕西麦科奥特科技有限公司 Anticoagulant reversal agent and preparation method and application thereof

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE793059A (en) 1972-02-28 1973-04-16 Ritzerfeld Gerhard INCHING DEVICE FOR ROTARY PRESSES A
JPS5632477B2 (en) 1973-03-07 1981-07-28
DE2330742C2 (en) 1973-06-16 1982-07-29 Hoechst Ag, 6000 Frankfurt 1- (Oxoalkyl) -3-methyl-7-alkylxanthines, process for their preparation and pharmaceuticals containing them
JPS5610188B2 (en) 1973-09-14 1981-03-06
JPS5756481B2 (en) 1974-06-13 1982-11-30
CA1037234A (en) 1976-06-01 1978-08-29 Aluma Building Systems Incorporated Wall forming structure for poured concrete walls
FR2376188A1 (en) 1976-12-28 1978-07-28 Elf Union PROCESS FOR PREPARING COMPOSITIONS OF POLYMERIC BITUMES
JPS54120627A (en) 1978-03-13 1979-09-19 Nittetsu Kakoki Kk Regenaration of asphalt concrete
JPS5576876A (en) 1978-12-05 1980-06-10 Grelan Pharmaceut Co Ltd Preparation of 1-(oxoalkyl)-3,7-dimethylxanthine derivatne
JPS5581055A (en) 1978-12-12 1980-06-18 Kubota Ltd Drawing device of pipe
JPS55122779A (en) 1979-03-13 1980-09-20 Maruko Seiyaku Kk Preparation of theobromine derivative
CS201558B1 (en) 1979-05-14 1980-11-28 Pavol Kovar Method of preparing 1-/5-oxohexyl/-3,7-dimethylxanthine
JPS5677279A (en) 1979-11-28 1981-06-25 Ota Seiyaku Kk Preparation of xanthine derivative
JPS56125451A (en) 1980-03-08 1981-10-01 Mitsubishi Gas Chem Co Inc Production of modified asphalt
JPS5762278A (en) 1980-10-01 1982-04-15 Sagami Chem Res Center Theobromine derivative and its preparation
JPS5780385A (en) 1980-11-05 1982-05-19 Mitsubishi Petrochem Co Ltd Preparation of 1-((omega-1)-oxoalkyl)-3,7-dialkylxanthine
JPS5785387A (en) 1980-11-14 1982-05-28 Teikoku Chem Ind Corp Ltd Preparation of 1-(-5'-oxohexyl)-3,7-dimethylxanthine
JPS5798284A (en) 1980-12-10 1982-06-18 Kawashima Yakuhin Kaihatsu Kk Preparation of 1-(5-oxohexyl)-3,7-dimethylxanthine
JPS5838284B2 (en) 1981-04-14 1983-08-22 ミサワホ−ム株式会社 Demolding equipment
JPS57200391A (en) 1981-06-02 1982-12-08 Daito Koeki Kk 1-(5-oxo-2-hexenyl)3,7-dimethylxanthine
JPS58134092A (en) 1982-02-05 1983-08-10 Sagami Chem Res Center Theobromine derivative
JPS58150594A (en) 1982-03-03 1983-09-07 Daito Koeki Kk Preparation of xanthine derivative
CS237719B1 (en) 1983-05-12 1985-10-16 Jan Jendrichovsky Process for the preparation of dimethyl (5-oxohexyl) xanthines
DE3508097A1 (en) 1984-07-21 1986-02-06 Hoechst Ag, 6230 Frankfurt COMBINATION PRODUCT MADE OF XANTHINE DERIVATIVES AND O-ACETYLSALICYL ACID OR THEIR PHARMACOLOGICALLY COMPATIBLE SALTS AND THE USE THEREOF
DD274334A3 (en) 1985-12-17 1989-12-20 Dresden Arzneimittel PROCESS FOR PREPARING PURE 3,7-DIMETHYL-1- (5-OXOHEXYL) -XANTHINE
IL100533A (en) 1986-12-31 1994-05-30 Hoechst Roussel Pharma Pharmaceutical compositions containing xanthine derivatives for treating hiv and related disease states
CS263595B1 (en) 1988-01-06 1989-04-14 Rybar Alfonz Process for preparing 7-n-propyl-3-methyl 3,7-dihydro-1H-purine-2,6-dione
JP2661666B2 (en) 1988-02-19 1997-10-08 ヘキスト薬品工業株式会社 Anti-peptic ulcer agent
IT1231779B (en) 1989-08-09 1991-12-21 Eniricerche Spa PROCEDURE FOR OXIDATION OF PARAFFINIC COMPOUNDS.
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
DE3942872A1 (en) 1989-12-23 1991-06-27 Hoechst Ag METHOD FOR THE ENANTIOSELECTIVE PRESENTATION OF ((OMEGA) -1) -HYDROXYALKYLXANTHINES
US5112827A (en) * 1990-05-18 1992-05-12 Board Of Regents, The University Of Texas System Drug to reverse fatty liver and atheromatous lesions
WO1992007566A2 (en) 1990-11-01 1992-05-14 Board Of Regents, The University Of Texas System Antifungal activity of and prevention of drug induced nephrotoxicity by methylxanthine analogues
ES2087205T3 (en) 1990-11-07 1996-07-16 Hoechst Roussel Pharma USE OF XANTHINES FOR THE PREPARATION OF AN EFFECTIVE MEDICATION TO INHIBIT THE REPLICATION OF HUMAN RETROVIRUSES.
EP0493682A3 (en) 1990-11-30 1992-11-19 Hoechst-Roussel Pharmaceuticals Incorporated Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans
EP0490181A1 (en) 1990-11-30 1992-06-17 Hoechst-Roussel Pharmaceuticals Incorporated Use of xanthines for preparation of a medicament having immunosuppressing activity
US5763446A (en) 1992-03-26 1998-06-09 University Of Southern California Use of pentoxifylline and other tumor necrosis factor blockers for the treatment of aids-associated optic neuropathy and other central nervous system diseases
US5804584A (en) * 1992-11-16 1998-09-08 Cell Therapeutics, Inc. Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
HUT68560A (en) 1993-08-02 1995-04-27 Chinoin Gyogyszer Es Vegyeszet The use of xantine derivatives for promotion of healing of operative lesions
JP3696884B2 (en) * 1994-03-25 2005-09-21 アイソテクニカ、インコーポレーテッド Enhancement of drug efficacy by deuteration
WO1995031450A1 (en) 1994-05-16 1995-11-23 Cell Therapeutics, Inc. Asymmetric synthesis of chiral secondary alcohols
AU3539795A (en) 1994-08-25 1996-03-14 Medical University Of South Carolina Methods of treating cold symptoms using pentoxifylline
DE4430128A1 (en) 1994-08-25 1996-02-29 Hoechst Ag Combination preparation with immunosuppressive, cardiovascular and cerebral effects
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
DE19544768C1 (en) 1995-11-30 1997-07-10 Rentschler Arzneimittel Use of a combination of pentoxifylline with type I interferons to treat multiple sclerosis
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US5985592A (en) 1997-06-05 1999-11-16 Dalhousie University Uses for pentoxifylline or functional derivatives/metabolites thereof
US6248889B1 (en) 1998-11-20 2001-06-19 3M Innovative Properties Company Process for converting an alcohol to the corresponding fluoride
US6417208B1 (en) 1999-02-05 2002-07-09 Albert Einstein College Of Medicine Of Yeshiva University Method of identification of inhibitors of PDE1C
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
GB0102107D0 (en) 2001-01-26 2001-03-14 Syngenta Ltd Chemical process
HU229938B1 (en) 2001-05-03 2015-01-28 Hoffmann La Roche Pharmaceutical dosage form of amorphous nelfinavir mesylate
US6737042B2 (en) 2001-05-24 2004-05-18 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
WO2003013568A1 (en) 2001-08-02 2003-02-20 Ortho-Mcneil Pharmaceutical, Inc. Cytokine modulation therapy
MXPA04004170A (en) 2001-11-02 2004-09-06 Pfizer Prod Inc Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors.
MXPA04008195A (en) 2002-03-14 2004-11-26 Bayer Pharmaceuticals Corp Methods of treating diabetes using pde 11a inhibitors.
DE10214228A1 (en) 2002-03-22 2003-10-02 Bdd Group Holding Ag Zug Deuterated substituted indoles and medicinal products containing these compounds
US20050107420A1 (en) * 2002-05-23 2005-05-19 Boehringe Ingelheim Pharma Gmbh & Co. Kg Combination of a PDE4 inhibitor and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
AR045696A1 (en) 2003-06-30 2005-11-09 Altana Pharma Ag PIRROLODIHYDROISOQUINOLINE DERIVATIVES AS PDE10 INHIBITORS
CA2534432A1 (en) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
WO2005023193A2 (en) 2003-09-04 2005-03-17 Interleukin Genetics, Inc. Methods of treating endometriosis
EP1755611A1 (en) 2004-06-07 2007-02-28 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
DE602005010899D1 (en) 2004-09-27 2008-12-18 Sigmoid Pharma Ltd MICRO CAPSULES WITH A METHYLXANTHINE AND A CORTICOSTEROID
JP2008514706A (en) 2004-09-29 2008-05-08 コーディス・コーポレイション Pharmaceutical dosage forms of stable amorphous rapamycin-like compounds
JP2009511481A (en) * 2005-10-06 2009-03-19 オースペックス・ファーマシューティカルズ・インコーポレイテッド Gastric H +, K + -ATPase deuteration inhibitors with enhanced therapeutic properties
US20090239886A1 (en) * 2008-02-29 2009-09-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives

Also Published As

Publication number Publication date
JP5292516B2 (en) 2013-09-18
JP2013503894A (en) 2013-02-04
PT2473053E (en) 2015-09-14
US20110053961A1 (en) 2011-03-03
AU2010289465B2 (en) 2016-03-10
MX2012002705A (en) 2012-04-02
SI2473053T1 (en) 2015-10-30
ES2542401T3 (en) 2015-08-05
HK1170377A1 (en) 2013-03-01
EA201270339A1 (en) 2012-09-28
PH12012500278A1 (en) 2012-10-22
ME02177B (en) 2015-10-20
CA2771123A1 (en) 2011-03-10
HUE026800T2 (en) 2016-07-28
CA2771123C (en) 2017-11-14
PL2473053T3 (en) 2015-10-30
BR112012008108B1 (en) 2019-10-22
BR112012008108A2 (en) 2015-09-22
EP2963040A1 (en) 2016-01-06
CN102480968A (en) 2012-05-30
EP2473053A4 (en) 2013-03-27
CN102480968B (en) 2015-01-07
EP2473053B1 (en) 2015-04-22
EA023809B1 (en) 2016-07-29
CN104478881A (en) 2015-04-01
EP2473053A1 (en) 2012-07-11
HRP20150797T1 (en) 2015-09-11
AU2010289465A1 (en) 2012-03-01
ZA201201295B (en) 2012-10-31
KR20120050509A (en) 2012-05-18
KR101591137B1 (en) 2016-02-02
DK2473053T3 (en) 2015-07-27
WO2011028922A1 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
IN2012DN01641A (en)
WO2009108383A3 (en) Substituted xanthine derivatives
IN2012DN01642A (en)
CA2871471C (en) Dna-pk inhibitors
MX2009008253A (en) Kinase inhibitors.
MX2012000709A (en) Pyrrolopyridine inhibitors of kinases.
MX2009009590A (en) Aminopyrimidines useful as inhibitors of protein kinases.
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
MX2015012502A (en) Dna-pk inhibitors.
MD20160136A2 (en) Substituted dihydroisoquinolinone compounds
MX2011009796A (en) Inhibitors of pi3 kinase.
UA110197C2 (en) To novel compounds which are effective as an inhibitor for xanthine oxidase, a process for preparing the same, and a pharmaceutical composition comprising a therapeutically effective amount of the same
MX350761B (en) Isoindolinone inhibitors of phosphatidylinositol 3-kinase.
MX2009009592A (en) Aminopyridines useful as inhibitors of protein kinases.
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
MX2011013032A (en) Inhibitors of phosphatidylinositol 3-kinase.
MX2009011811A (en) Aminopyrimidines useful as kinase inhibitors.
MX2009000169A (en) Purinone derivatives as hm74a agonists.
MX337849B (en) Compositions and methods for inhibition of the jak pathway.
JO2682B1 (en) 7-ALkynyl-1,8-Naphthyridone Derivatives, Preparation Thereof And Therapeutic Use Thereof
PH12017500089B1 (en) Aldosterone synthase inhibitors
MX2011008645A (en) Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase.
WO2013155465A8 (en) Substituted xanthine derivatives
MX2011012524A (en) Inhibitors of c-met protein kinase.
WO2010107791A3 (en) Pyrazinoisoquinoline compounds